Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.66 - $2.42 $40,875 - $59,590
24,624 New
24,624 $46,000
Q1 2022

May 16, 2022

SELL
$4.81 - $6.99 $337,123 - $489,915
-70,088 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$5.97 - $7.93 $151,315 - $200,993
-25,346 Reduced 26.56%
70,088 $477,000
Q3 2021

Nov 15, 2021

BUY
$4.79 - $6.68 $213,159 - $297,266
44,501 Added 87.37%
95,434 $581,000
Q2 2021

Aug 16, 2021

BUY
$5.35 - $6.35 $272,491 - $323,424
50,933 New
50,933 $301,000
Q1 2020

May 15, 2020

SELL
$2.87 - $5.49 $41,709 - $79,786
-14,533 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$3.84 - $4.86 $55,806 - $70,630
14,533 New
14,533 $61,000
Q3 2019

Nov 14, 2019

SELL
$4.86 - $6.05 $268,111 - $333,760
-55,167 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$4.51 - $6.6 $248,803 - $364,102
55,167 New
55,167 $310,000
Q1 2019

May 15, 2019

SELL
$5.16 - $6.85 $135,682 - $180,120
-26,295 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$4.89 - $7.16 $48,112 - $70,447
9,839 Added 59.79%
26,295 $133,000
Q3 2018

Nov 14, 2018

BUY
$6.89 - $7.78 $113,381 - $128,027
16,456 New
16,456 $119,000

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $351M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.